For the data behind the commentary, download the full Q3 2026 UK Life Sciences Report
London's Science & Innovation Ecosystem Set to Service AI Boom
Artificial intelligence (AI) is becoming increasingly central to the UK’s science and innovation ecosystem. Rather than developing solely as a standalone sector, it is being embedded across drug discovery, diagnostics, biotechnology and medical research, changing how scientific businesses operate and the types of space they require. AI and computational science occupiers could become an important source of demand where developments provide sufficient power, flexible configurations and access to London’s research and talent ecosystem.
In October, the London Initiative for Safe AI pre-let approximately 82,000 sq ft at Reflector, part of Tribeca in the King’s Cross Knowledge Quarter. The transaction illustrates the growing convergence between AI and science. AI is increasingly supporting scientific research through data analysis, predictive modelling and automation, helping to accelerate discovery and shorten development timelines. London-headquartered Isomorphic Labs exemplifies this convergence. Its £1.6 billion Series B was the UK’s largest life sciences fundraising round of 2026 to date and will support the expansion of its AI-driven drug-design platform.
Anthropic is also moving beyond supplying AI tools to become a direct participant in life sciences research. It has established a wet lab in the San Francisco Bay Area, taken 24,000 sq ft at the One Kendall Square office and laboratory campus in Cambridge, Massachusetts, and have recently acquired Mithril Medicine, a one-person biotech developing treatments for rare muscular dystrophies. Alongside the launch of Claude Science, a dedicated research workbench, these moves place Anthropic directly within the drug-development process.
Our analysis of PitchBook data reinforces this picture. Among science and innovation companies founded between 2023 and 2025, 74% are AI-tagged. Of this cohort, 63% are now headquartered in London, while the capital accounts for 69% of all AI-tagged companies. More than four in five (81%) of the London-headquartered businesses carry an AI tag.
This growth has implications for future science and innovation space. Computational businesses may not always require traditional wet laboratories, but they benefit from proximity to research institutions, life sciences companies, specialist talent and venture capital, many of whom occupy the traditional wet laboratories. London accounted for 52% of the £3.6 billion raised by UK life sciences companies, while hybrid campuses combining laboratories with computational, collaborative and flexible space could appeal to an increasingly diverse occupier base.
Disclaimer: The views expressed in this report are provided for general informational purposes only and do not constitute investment advice or a solicitation.
Q3 2026 UK LIFE SCIENCES MARKETBEAT
Contacts
Current UK MarketBeat Reports
MarketBeat
UK London Office Marketbeat Report
MarketBeat
UK Regional Offices MarketBeat
MarketBeat
UK Industrial Marketbeat Reports
MarketBeat
Insights
MarketBeat
UK London Office Marketbeat Report
MarketBeat
UK Life Science Marketbeat Report
Research
The Income Era: Why European Living’s Next Phase Will Be Defined by Income
The European Living market has spent the past decade moving firmly into the institutional mainstream
Insights • Economy
2026 Autumn Budget: Implications for real estate
MarketBeat
UK Regional Offices MarketBeat
MarketBeat
UK Industrial Marketbeat Reports
MarketBeat
UK Economy & Housing Marketbeat Reports
Insights • Economy
Cost Inflation: Are Fundamentals Still Supporting Fee Growth?
MarketBeat
UK Hospitality Marketbeat Reports
Insights • Economy
Autumn Budget: Implications for real estate
Article
Trade Shifts: U.S. Investor Demand & Healthcare